Analysts See $-0.81 EPS for Insmed Incorporated (INSM)

April 26, 2018 - By Linda Rogers

Insmed Incorporated (NASDAQ:INSM) LogoInvestors sentiment decreased to 1 in Q4 2017. Its down 2.74, from 3.74 in 2017Q3. It is negative, as 27 investors sold Insmed Incorporated shares while 40 reduced holdings. 18 funds opened positions while 49 raised stakes. 73.21 million shares or 49.25% less from 144.25 million shares in 2017Q3 were reported.
The Pennsylvania-based Emerald Advisers Inc Pa has invested 1.03% in Insmed Incorporated (NASDAQ:INSM). Qs Limited Liability invested in 75,620 shares. Northern Tru reported 953,984 shares or 0.01% of all its holdings. Principal Fincl Gru has invested 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). J Goldman & Company Ltd Partnership invested 0.03% in Insmed Incorporated (NASDAQ:INSM). Comml Bank Of Montreal Can invested in 952 shares or 0% of the stock. Private Ocean Limited Liability Com holds 2,500 shares. Baker Bros Advsr Lp holds 0.19% or 700,000 shares in its portfolio. 155,000 were accumulated by Omega Advsrs. Strs Ohio reported 1,900 shares stake. Victory Capital Mgmt reported 598,250 shares. Cornerstone Capital Limited Liability Company holds 33,408 shares or 0.01% of its portfolio. 24,458 were accumulated by Financial Bank Of America Corp De. Wellington Management Grp Inc Limited Liability Partnership, Massachusetts-based fund reported 81,758 shares. Quantbot Tech Lp invested in 1,635 shares.

Analysts expect Insmed Incorporated (NASDAQ:INSM) to report $-0.81 EPS on May, 2.They anticipate $0.21 EPS change or 35.00 % from last quarter’s $-0.6 EPS. After having $-0.85 EPS previously, Insmed Incorporated’s analysts see -4.71 % EPS growth. The stock increased 0.68% or $0.17 during the last trading session, reaching $25.17. About 543,087 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 31.10% since April 26, 2017 and is uptrending. It has outperformed by 19.55% the S&P500.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Among 6 analysts covering Insmed (NASDAQ:INSM), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insmed had 9 analyst reports since October 30, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, January 4 by Stifel Nicolaus. The firm has “Buy” rating given on Thursday, November 2 by Stifel Nicolaus. Credit Suisse upgraded the shares of INSM in report on Monday, April 23 to “Outperform” rating. Leerink Swann maintained Insmed Incorporated (NASDAQ:INSM) rating on Wednesday, March 14. Leerink Swann has “Buy” rating and $39.0 target. The stock has “Buy” rating by Robert W. Baird on Monday, October 30. The stock of Insmed Incorporated (NASDAQ:INSM) has “Buy” rating given on Monday, November 6 by H.C. Wainwright. The firm has “Buy” rating given on Thursday, January 4 by Robert W. Baird. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, January 4 report.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $1.93 billion. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.